Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2016

01-01-2016 | Gynecologic Oncology

Tumor Size, an Additional Prognostic Factor to Include in Low-Risk Endometrial Cancer: Results of a French Multicenter Study

Authors: Geoffroy Canlorbe, MD, Sofiane Bendifallah, MD, Enora Laas, MD, Emilie Raimond, MD, Olivier Graesslin, MD, PhD, Delphine Hudry, MD, Charles Coutant, MD, PhD, Cyril Touboul, MD, PhD, Géraldine Bleu, MD, Pierre Collinet, MD, PhD, Annie Cortez, MD, Emile Daraï, MD, PhD, Marcos Ballester, MD, PhD

Published in: Annals of Surgical Oncology | Issue 1/2016

Login to get access

Abstract

Background

Additional tools are needed to improve the selection of women with early-stage endometrial cancer (EC) at increased risk of nodal metastases and/or recurrence to adapt surgical staging and adjuvant therapies. The aim of this study was to assess the impact of EC tumor size on nodal status and recurrence-free survival (RFS) according to European risk groups for recurrence.

Methods

Data of 633 women with early-stage EC who received primary surgical treatment between 2001 and 2012 were abstracted from a multicenter database. Optimal tumor size cut-offs were determined by a minimal p value approach according to final nodal status. Logistic regression was used to determine the impact of defined tumor size on nodal involvement, and the Kaplan–Meier method was used to estimate the survival distribution.

Results

The number of women with final low-, intermediate-, and high-risk EC was 302, 204, and 127, respectively. Tumor size was correlated with nodal status and RFS in women with low-risk EC, while no correlation was found for women with intermediate/high-risk EC. Tumor size ≥35 mm emerged as the optimal threshold for a higher rate of nodal involvement (odds ratio 4.318, 95 % CI 1.13–16.51, p = 0.03) and a lower RFS (p = 0.005) in women with low-risk EC.

Conclusion

Tumor size is an independent prognostic factor of lymph node involvement in women with low-risk EC and could be a valuable additional histological criterion for selecting women at increased risk of lymph node metastases to better adapt surgical staging.
Literature
1.
2.
Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi33-8.PubMedCrossRef
3.
Querleu D, Planchamp F, Narducci F, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Societe Francaise d’Oncologie Gynecologique. Int J Gynecol Cancer. 2011;21(5):945–50.PubMedCrossRef
4.
Panici PB, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707–16.CrossRef
5.
Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.PubMedCrossRef
6.
Ballester M, Dubernard G, Lecuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12(5):469–76.PubMedCrossRef
7.
Gusberg SB, Jones HC Jr, Tovell HM. Selection of treatment for corpus cancer. Am J Obstet Gynecol. 1960;80:374–80.PubMedCrossRef
8.
Schink JC, Rademaker AW, Miller DS, Lurain JR. Tumor size in endometrial cancer. Cancer. 1991;67(11):2791–4.PubMedCrossRef
9.
Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182(6):1506–19.PubMedCrossRef
10.
Convery PA, Cantrell LA, Di Santo N, Broadwater G, Modesitt SC, Secord AA, et al. Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. Gynecol Oncol. 2011;123(1):65–70.PubMedCrossRef
11.
Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012;119(2 Pt 1):286–92.PubMedPubMedCentralCrossRef
12.
AlHilli MM, Podratz KC, Dowdy SC, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013;128(2):294–9.PubMedCrossRef
13.
Vargas R, Rauh-Hain JA, Clemmer J, et al. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014;133(2):216–20.PubMedCrossRef
14.
Bendifallah S, Canlorbe G, Huguet F, et al. A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French Multicentre Study. Ann Surg Oncol. 2014;21(13):4239–45.PubMedCrossRef
15.
Gilani S, Anderson I, Fathallah L, Mazzara P. Factors predicting nodal metastasis in endometrial cancer. Arch Gynecol Obstet. 2014;290(6):1187–93.PubMedCrossRef
16.
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103–4.PubMedCrossRef
17.
Briet JM, Hollema H, Reesink N, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005;96(3):799–804.PubMedCrossRef
18.
Delpech Y, Cortez A, Coutant C, Callard P, Uzan S, Darai E, et al. The sentinel node concept in endometrial cancer: histopathologic validation by serial section and immunohistochemistry. Ann Oncol. 2007;18(11):1799–803.PubMedCrossRef
19.
Ballester M, Canlorbe G, Cortez A, et al. Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer. Gynecol Oncol. 2013;130(3):457–62.PubMedCrossRef
20.
Chi DS, Barakat RR, Palayekar MJ, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18(2):269–73.PubMedCrossRef
21.
Nugent EK, Bishop EA, Mathews CA, et al. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012;125(1):94–8.PubMedCrossRef
22.
Bendifallah S, Genin AS, Naoura I, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207(3):197 e1–8.
23.
Todo Y, Choi HJ, Kang S, et al. Clinical significance of tumor volume in endometrial cancer: a Japan-Korea cooperative study. Gynecol Oncol. 2013;131(2):294–8.PubMedCrossRef
24.
Doll KM, Tseng J, Denslow SA, Fader AN, Gehrig PA. High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol. 2014;132(1):44–9.PubMedCrossRef
25.
Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375(9721):1165–72.PubMedCrossRef
Metadata
Title
Tumor Size, an Additional Prognostic Factor to Include in Low-Risk Endometrial Cancer: Results of a French Multicenter Study
Authors
Geoffroy Canlorbe, MD
Sofiane Bendifallah, MD
Enora Laas, MD
Emilie Raimond, MD
Olivier Graesslin, MD, PhD
Delphine Hudry, MD
Charles Coutant, MD, PhD
Cyril Touboul, MD, PhD
Géraldine Bleu, MD
Pierre Collinet, MD, PhD
Annie Cortez, MD
Emile Daraï, MD, PhD
Marcos Ballester, MD, PhD
Publication date
01-01-2016
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4583-3

Other articles of this Issue 1/2016

Annals of Surgical Oncology 1/2016 Go to the issue

Breast Oncology

Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction

Colorectal Cancer

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The Need for Accessible Data in Real Time

Bone and Soft Tissue Sarcomas

Metastatic Potential of Grade I Chondrosarcoma of Bone: Results of a Multi-institutional Study

Translational Research and Biomarkers

TGFBI Expression in Cancer Stromal Cells is Associated with Poor Prognosis and Hematogenous Recurrence in Esophageal Squamous Cell Carcinoma

Translational Research and Biomarkers

Effect of Duration of Ex Vivo Ischemia Time and Storage Period on RNA Quality in Biobanked Human Renal Cell Carcinoma Tissue

Breast Oncology

Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer